Clinical Trial Update: ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants [Phase 3]

View source ↗

Summary

Phase 3 trial comparing brigatinib to crizotinib in ALK-positive advanced non-small cell lung cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)
• Crizotinib (crizotinib)

Snippet

Sponsor: Ariad Pharmaceuticals | Conditions: Non-small Cell Lung Cancer, Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-08-20